ArticleGut2021
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020Pooled it
- Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors.Immunity, inflammation and disease · 2023Article
- Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019.Journal of medical virology · 2023Article
- Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.Frontiers in immunology · 2023Review
- Article
- Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.Process biochemistry (Barking, London, England) · 2022Article
- Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Therapeutic role of immunomodulators during the COVID-19 pandemic- a narrative review.Postgraduate medicine · 2022Review
- Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report.BMC gastroenterology · 2022Article
- Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.Frontiers in immunology · 2022Review
- I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections.Frontiers in immunology · 2022Review
- Targeting TNF-α for COVID-19: Recent Advanced and Controversies.Frontiers in public health · 2022Review
- Infliximab rescue therapy in a patient with acute severe ulcerative colitis and coronavirus disease 2019 followed by Escherichia coli 0157:H7 infection: a case report.Croatian medical journal · 2021Article
- SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.International immunopharmacology · 2021Review
- Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy.Journal of gastroenterology and hepatology · 2021Observational
- Article
- Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?Digestive diseases and sciences · 2021Review
- COVID-19 and the Use of Immunomodulatory Agents in OphthalmologyTurkish journal of ophthalmology · 2021Review
- The Role of the PFNA Operon of Bifidobacteria in the Recognition of Host's Immune Signals: Prospects for the Use of the FN3 Protein in the Treatment of COVID-19.International journal of molecular sciences · 2021Review
- Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis.World journal of gastroenterology · 2021Review
Corrections and comments
- Comment on
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.